Flawless Pharma Inks API Deal with European and African Company

Flawless Pharma Pvt. Ltd. has entered into a technology transfer agreement with a large European contract development and manufacturing organization (CDMO) and a top African enterprise in Africa for the export and supply of the active ingredient of anti-cancer and anti-viral medications. The agreement's total value will contribute significantly to Flawless Pharma's annual business revenues.

Flawless Pharma's product portfolio focuses on APIs and advanced intermediates in multiple therapy areas , such as analgesic, antipyretic, and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand as per sustainabilitynext.

Flawless Pharma is one of the fastest-growing pharmaceutical firms in the Middle East and Africa, with a strong pan-African footprint and operations in over 50 countries. Flawless Pharma has been providing API (Active Pharmaceutical Ingredient) manufacturing and marketing services for over ten years, from process development to commercial manufacture in full regulatory compliance, to provide a robust and secure supply chain of Pharmaceutical APIs. Dr Sujeet Kumar Singh, Managing Director of Flawless Pharma Pvt. Limited said “We are pleased to announce the partnership with the two of the top European & African Pharma Company to supply of the active ingredient of the Anti-cancer and Anti-viral drugs with a technology transfer agreement. The combined value of the deal will be to the tune of US $ 120 Mn. Our new collaboration with the European & African market demonstrates Flawless Pharma’s deep commitment to making equitable and affordable access to Anti-cancer and anti-viral drugs through the collaborative technology transfer agreement a reality for people living with multi prolonged diseases in low- and middle-income countries which will transform communities and make life better for people throughout the continent.